Voluntary Announcement

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in the Treatment of Metastatic ER+/HER2- Breast Cancer

Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) today announced a clinical trial collaboration and supply agreement (the “Collaboration Agreement”) with Pfizer Inc. to develop the combination of Ascentage Pharma’s lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, in combination with Pfizer’s IBRANCE® (palbociclib), a CDK4/6 inhibitor, in the treatment of patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Under the terms of the agreement, Ascentage Pharma is responsible for conducting the trial and Pfizer is responsible for supplying study drug for a global, multicenter, open-label Phase Ib/II dose-escalation and expansion study, which is designed to evaluate the safety, tolerability, and anticancer activity of lisaftoclax in combination with Palbociclib in patients with metastatic breast cancer.

APG-2575 is a novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma. APG-2575 is designed to treat a variety of malignancies by selectively blocking the Bcl-2 protein to restore the normal apoptosis process in cancer cells, or programmed cell death. Globally, APG-2575 is one of the few Bcl-2 selective inhibitors in clinical development after VENCLEXTA® (venetoclax). Since June 2021, the Company has received approvals and clearances in China and the US for the study of APG-2575 as a single agent or in combinations in ER+ breast cancer and other solid tumors. Previously, Ascentage Pharma also advanced its clinical development of APG-2575 in a variety of hematologic malignancy indications in the US, Europe, China, and Australia.

About Ascentage Pharma

Ascentage Pharma is a China-based, globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB (Chronic hepatitis B), and age-related diseases. On October 28, 2019, Ascentage Pharma became listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.
Ascentage Pharma has its own platform for developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Company has built a pipeline of eight type I small molecule clinical drug candidates which have entered the clinical development stage, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The Company is conducting more than 40 Phase I/II clinical trials in China, the US, Australia and Europe. The Company has been designated for multiple major national R&D projects in China, including five Major New Drug Development Projects, one Enterprise Innovative Drug Incubator Base status, four Innovative Drug Research and Development Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. HQP1351, the Company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and a New Drug Application (NDA) for the drug candidate has been submitted and subsequently granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) in China. As at the date of this announcement, Ascentage Pharma has obtained a total of 12 ODDs from the US FDA for 4 of the Company’s investigational drug candidates.

Leveraging its robust research and development capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights, and entered into global partnerships with numerous leading biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The Company has built a global and talented team with experience in the research and development of innovative drugs and clinical development, and is setting up its commercial manufacturing and sales and marketing teams with high standards. Ascentage Pharma aims to continuously strengthen its research and development capabilities and accelerate the clinical development progress of its product pipeline to fulfil its mission of ‘addressing unmet clinical needs of patients in China and around the world’ for the benefit of more patients.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-2575 successfully.

By order of the Board

Ascentage Pharma Group International

Dr. Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, November 8, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.